L-Methionine-DL-sulfoximine

L-Methionine-DL-sulfoximine (MSX; MSO), a highly specific and irreversible inhibitor of Glutamine synthetase (GS), is also a potent convulsant which metabolically and morphologically primarily affects astroglia. L-Methionine-DL-sulfoximine has been employed to inhibit the Gln-dependent ammonia-stimulated neuronal toxicity in vitro, potentiating Gln deficit-dependent depression. L-Methionine-DL-sulfoximine tremendously increases the rate of release of fixed nitrogen in cyanobacteria. L-Methionine-DL-sulfoximine is a promising candidate for research in biofertilizers and convulsive seizures (CS)^{[1][2][3][4][5]}. In Vivo: L-Methionine-DL-sulfoximine (75 mg/kg, i.p., 210 min) exerts no affect on the hippocampal Gutamine synthetase (GS) activity and the expression of GS protein for the first 150 min, but significantly decreases the activity of GS during 165-210 min in rats. Additionally, L-Methionine-DL-sulfoximine also reduces the intensity of convulsive seizures (CS) caused by Pilocarpine (Pilo) (HY-B0726A) administration and seizure in rats^[1].
L-Methionine-DL-sulfoximine (75 mg/kg, i.p.) reduces D-Asp release evoked by K⁺-induced depolarization and unchanges Glu uptake in the hippocampus and enthorhinal cortex of temporal lobe epilepsy (TLE) model rats^[4].